Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:1525-7304
-
Container-title:Clinical Lung Cancer
-
language:en
-
Short-container-title:Clinical Lung Cancer
Author:
Acker FabianORCID, Klein Alexandra, Rasokat Anna, Eisert Anna, Kron Anna, Christopoulos Petros, Stenzinger Albrecht, Kulhavy Jonas, Hummel Horst-Dieter, Waller Cornelius F., Hummel Anne, Rittmeyer Achim, Kropf-Sanchen Cornelia, Zimmermann Heiner, Lörsch Alisa, Kauffmann-Guerrero Diego, Schütz Maret, Herster Franziska, Thielert Franziska, Demes Melanie, Althoff Friederike C., Aguinarte Lukas, Heinzen Sophie, Rost Maximilian, Schulte Hanna, Stratmann Jan, Rohde Gernot, Büttner Reinhard, Wolf Jürgen, Sebastian Martin, Michels Sebastian
Reference31 articles.
1. A prospective, molecular epidemiology study of EGFR mutations in asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J Thorac Oncol,2014 2. Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315);Griesinger;Lung Cancer,2021 3. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020 4. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon–small-cell lung cancer with EGFR exon 19 deletion or L858R mutations;Lu;J Clin Oncol,2022 5. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non–small-cell lung cancer: results from LASER301;Cho;J Clin Oncol,2023
|
|